| Daniel Y Ryu, MD | |
|
2322 E 22nd St, Svch Occupational Medicine, Cleveland, OH 44115-3176 | |
| (216) 363-2691 | |
| (216) 694-4665 |
| Full Name | Daniel Y Ryu |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine |
| Location | 2322 E 22nd St, Cleveland, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972593309 | NPI | - | NPPES |
| 2546187 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0500X | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine | 35-067499 (Ohio) | Primary |
| Entity Name | Alliant Treatment Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134649676 PECOS PAC ID: 9133486285 Enrollment ID: O20171128003674 |
News Archive
Impax Laboratories, Inc. confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application for generic version of Cymbalta® delayed-release (duloxetine hydrochloride) 20, 30 and 60 mg capsules.
The National Medical Association, the nation's oldest and largest organization representing the interests of 30,000 African American physicians will hold a press conference to address health care reform legislation and its impact on health disparities.
ETH researchers have deconstructed the mechanisms that control wound healing and scar formation in more detail.
You can find the recommended dietary allowance on the nutrition labels of all your processed food. Food manufacturers are obliged to list the nutritional value of their products, and therefore must mention the percent daily value of the RDA their product meets for certain nutrients.
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Y Ryu, MD 6935 Treeline Dr, Ste J, Brecksville, OH 44141-3393 Ph: (440) 746-2220 | Daniel Y Ryu, MD 2322 E 22nd St, Svch Occupational Medicine, Cleveland, OH 44115-3176 Ph: (216) 363-2691 |
News Archive
Impax Laboratories, Inc. confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application for generic version of Cymbalta® delayed-release (duloxetine hydrochloride) 20, 30 and 60 mg capsules.
The National Medical Association, the nation's oldest and largest organization representing the interests of 30,000 African American physicians will hold a press conference to address health care reform legislation and its impact on health disparities.
ETH researchers have deconstructed the mechanisms that control wound healing and scar formation in more detail.
You can find the recommended dietary allowance on the nutrition labels of all your processed food. Food manufacturers are obliged to list the nutritional value of their products, and therefore must mention the percent daily value of the RDA their product meets for certain nutrients.
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.
› Verified 8 days ago
Francis J Yuhas, D.O. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 4660 Hinckley Industrial Pkwy, Cleveland, OH 44109 Phone: 615-778-4066 | |
Dr. Joseph C Eshelman, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 5500 S Marginal Rd, Cleveland, OH 44103 Phone: 216-426-9020 | |
Irina Arkhipova-jenkins, M.D. Preventive Medicine Medicare: Medicare Enrolled Practice Location: Bariatric And Metabolic Institute 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-444-2200 | |
Patrick G Bray, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 2522 E 22nd St, Svch Occupational Medicine, Cleveland, OH 44115 Phone: 216-363-2691 Fax: 216-694-4665 | |
Dr. Zenobia K Tayeb, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 9500 Euclid Ave # Q2-1, Cleveland, OH 44195 Phone: 216-448-4325 | |
Kathleen M Fagan, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 11100 Euclid Avenue, Cleveland, OH 44106 Phone: 216-844-7700 Fax: 216-286-6299 | |
Scott E Singer, MD MPH Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 8555 Sweet Valley Dr, Cleveland, OH 44125 Phone: 216-328-2240 Fax: 216-642-7945 |